Characteristics of the patients at baseline
| Characteristic | Study group; no. (%) of patients*† | |
|---|---|---|
| Curcumin n = 304 | Placebo n = 302 | |
| Demographic | ||
| Age, yr, median (IQR) | 76 (71 to 80) | 76 (70 to 81) |
| Sex, women | 58 (19) | 47 (16) |
| Ethnicity, white | 298 (98) | 293 (97) |
| Comorbidities | ||
| Abdominal aortic aneurysm, mm diameter, median (IQR) | 57 (54 to 61) | 57 (55 to 60) |
| Current smoker | 94 (31) | 92 (30) |
| Diabetes mellitus | 73 (24) | 72 (24) |
| Congestive heart failure | 14 (5) | 13 (4) |
| Hypertension | 238 (78) | 224 (74) |
| Chronic obstructive pulmonary disease | 81 (27) | 86 (28) |
| Coronary artery disease, including angina | 184 (61) | 182 (60) |
| Prior stroke or transient ischemic attack | 42 (14) | 35 (12) |
| Gastroesophageal reflux disease | 74 (24) | 73 (24) |
| Medications | ||
| ACE-I or ARB | 178 (59) | 184 (61) |
| Diuretic | 101 (33) | 90 (30) |
| Calcium channel blocker | 94 (31) | 83 (27) |
| β-Blocker | 118 (39) | 128 (42) |
| Antiplatelet drug, including ASA | 211 (69) | 191 (63) |
| Anticoagulant | 18 (6) | 20 (7) |
| Oral hypoglycemic | 61 (20) | 58 (19) |
| Insulin | 6 (2) | 7 (2) |
| Statin | 212 (70) | 209 (69) |
| Physical examination | ||
| Weight, kg, median (IQR) | 83 (71 to 94) | 86 (74 to 98) |
| Body mass index > 35 kg/m2 | 25 (8) | 34 (11) |
| Systolic blood pressure, mm Hg | 134 (122 to 146) | 134 (122 to 146) |
| Diastolic blood pressure, mm Hg | 79 (70 to 85) | 78 (70 to 83) |
| Laboratory investigations: eGFR, mL/min per 1.73 m2 | ||
| 45 to < 60 | 61 (20) | 55 (18) |
| 30 to < 45 | 34 (11) | 24 (8) |
| < 30 | 12 (4) | 8 (3) |
Note: ACE-I = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, ASA = acetylsalicylic acid, eGFR = estimated glomerular filtration rate assessed with the Chronic Kidney Disease Epidemiology (CKD Epi) equation, IQR = interquartile range.
↵* Except where indicated otherwise.
↵† There were no significant differences between the 2 groups for any of the characteristics.